Phase i trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Gastrointestinal Neoplasms
  • Maximum Tolerated Dose

abstract

  • Paclitaxel at 65 mg/m(2), cisplatin (30 mg/m(2)), and irinotecan (50 mg/m(2)) given weekly can be safely administered to patients with solid tumor malignancies. To improve cumulative toxicities, a schedule modification was required (3-week cycle; 2-on, 1-off) Neutropenia was the most common DLT. This combination showed substantial activity, particularly in patients with gastric and esophageal adenocarcinoma, and phase II evaluation could be considered.

publication date

  • August 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3219507

Digital Object Identifier (DOI)

  • 10.1007/s10637-008-9194-4

PubMed ID

  • 18956138

Additional Document Info

start page

  • 366

end page

  • 73

volume

  • 27

number

  • 4